Phosphorylated Tau 217

Tau is a microtubule-associated protein that normally stabilizes the internal structural framework of neurons. In Alzheimer's disease and related tauopathies, tau becomes hyperphosphorylated — meaning phosphate groups are added at abnormal sites along the protein chain. This hyperphosphorylation causes tau to detach from microtubules, misfold, and aggregate into neurofibrillary tangles, one of the two hallmark pathologies of Alzheimer's disease alongside amyloid plaques. Phosphorylation at the threonine-217 site (p-tau 217) appears to be particularly closely linked to the presence of amyloid pathology, even before tau tangles are widespread.

Blood-based p-tau 217 tests have shown diagnostic performance approaching that of cerebrospinal fluid biomarkers and PET imaging in distinguishing Alzheimer's disease from other causes of cognitive decline. In head-to-head comparisons, p-tau 217 has outperformed other phosphorylated tau species (including p-tau 181 and p-tau 231) in accuracy for identifying amyloid-positive individuals. The ratio of p-tau 217 to non-phosphorylated tau 217 further enhances diagnostic precision by normalizing for individual variation in total tau production.

The clinical significance of p-tau 217 extends beyond diagnosis. Longitudinal studies have shown that p-tau 217 levels begin to rise years before the onset of cognitive symptoms, during the "preclinical" phase of Alzheimer's disease when brain pathology is accumulating silently. This early elevation positions p-tau 217 as a candidate biomarker for screening and for selecting participants in prevention trials targeting the earliest stages of the disease.

Prevena Health is exploring whether continuous monitoring of p-tau 217 levels may add value to Alzheimer's disease research and clinical care. Current blood-based p-tau 217 tests provide a single-point measurement that captures where a patient falls on the diagnostic spectrum at one moment. Longitudinal tracking — measuring how p-tau 217 levels change over weeks, months, or years — may reveal individual trajectories of pathological progression that single measurements cannot characterize.

By investigating continuous biomarker surveillance through a wearable platform, Prevena aims to support researchers studying the kinetics of tau phosphorylation in response to therapies, lifestyle interventions, or disease progression. This approach may complement existing diagnostic frameworks by providing temporal resolution that clinic-based blood draws cannot achieve, potentially helping to identify individuals transitioning from preclinical to prodromal Alzheimer's disease.